Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DURECT Corporation
  6. Summary
    DRRX   US2666051048

DURECT CORPORATION

(DRRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/19/2021 10/20/2021 10/21/2021 10/22/2021 10/25/2021 Date
1.15(c) 1.15(c) 1.17(c) 1.16(c) 1.15 Last
213 182 421 385 342 321 717 650 482 055 Volume
+0.88% 0.00% +1.74% -0.85% -0.86% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 8,56 M - -
Net income 2021 -40,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,27x
Yield 2021 -
Sales 2022 14,8 M - -
Net income 2022 -42,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -6,51x
Yield 2022 -
Capitalization 262 M 262 M -
Capi. / Sales 2021 30,6x
Capi. / Sales 2022 17,7x
Nbr of Employees 79
Free-Float 98,6%
More Financials
Company
DURECT Corporation is a biopharmaceutical company focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. DURÔÇĹ928 is a candidate in its Epigenetic Regulator Program.... 
More about the company
Ratings of DURECT Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about DURECT CORPORATION
10/07DURECT CORPORATION : Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Confere..
PR
09/23DURECT CORPORATION : Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2..
PR
09/15DURECT CORPORATION : Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTec..
PR
09/07DURECT CORPORATION : Fireside Chat at the H.C. Wainwright Annual Global Investment Confere..
PR
08/02DURECT : Chardan Suspends Coverage on Durect at Buy Rating With $8 Price Target
MT
08/02DURECT : Files for Up to $250 Million Mixed-Securities Shelf
MT
07/30DURECT : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
07/29DURECT : Q2 Earnings Snapshot
AQ
07/29DURECT CORPORATION ANNOUNCES SECOND : 30 p.m. ET (Form 8-K)
PU
07/29DURECT CORP : Results of Operations and Financial Condition, Financial Statements and Exhi..
AQ
07/29DURECT : Earnings Flash (DRRX) DURECT CORPORATION Reports Q2 Revenue $2.3M, vs. Street Est..
MT
07/29DURECT CORPORATION : Announces Second Quarter 2021 Financial Results and Update of Program..
PR
07/29Durect Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
07/22DURECT CORPORATION : to Announce Second Quarter 2021 Financial Results and Provide Busines..
PR
07/14DURECT CORPORATION : to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit
PR
More news
News in other languages on DURECT CORPORATION
05/04IRW-PRESS : Sernova Corp. : Sernova gibt die Berufung der erfahrenen Pharma-Führungskraft ..
2019Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on DURECT CORPORATION
More recommendations
Chart DURECT CORPORATION
Duration : Period :
DURECT Corporation Technical Analysis Chart | DRRX | US2666051048 | MarketScreener
Technical analysis trends DURECT CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 1,15 $
Average target price 6,33 $
Spread / Average Target 451%
EPS Revisions
Managers and Directors
James E. Brown President, Chief Executive Officer & Director
Michael H. Arenberg Chief Financial Officer & Secretary
David R. Hoffmann Chairman
Wei Qi Lin Executive Vice President-Research & Development
David J. Ellis Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
DURECT CORPORATION-43.96%264
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.08%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610